On June 17, 2008, Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced that HUMIRA(R) subcutaneous injection 40mg Syringe 0.8mL (referred to as HUMIRA hereinafter) will be available for the treatment of rheumatoid arthritis from June 18, 2008.
HUMIRA received approval for manufacturing and distribution in Japan on April 16, 2008, and was listed in the National Health Insurance drug price list on June 13, 2008. After its launch, Abbott and Eisai will take a one-brand, one-channel and two-promotion scheme to ensure provision of information on proper use of HUMIRA. Both Abbott and Eisai will provide specialist medical representatives (MRs), and Abbott will cooperate with Eisai's hospital MRs. The two companies will conduct postmarketing surveillance in patients receiving HUMIRA during a certain period of time after launching to promote the effective and safe use of HUMIRA.
The details can be read here.
No comments:
Post a Comment